CROSS COUNTRY HEALTHCARE INC (CCRN)
US2274831047 - Common Stock
We assign a fundamental rating of 5 out of 10 to CCRN. CCRN was compared to 107 industry peers in the Health Care Providers & Services industry. CCRN has an excellent financial health rating, but there are some minor concerns on its profitability. CCRN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year CCRN was profitable.
In the past year CCRN had a positive cash flow from operations.
In multiple years CCRN reported negative net income over the last 5 years.
Of the past 5 years CCRN 4 years had a positive operating cash flow.
1.2 Ratios
CCRN has a Return On Assets (-0.30%) which is comparable to the rest of the industry.
CCRN has a Return On Equity (-0.42%) which is comparable to the rest of the industry.
CCRN has a Return On Invested Capital (2.00%) which is in line with its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CCRN is significantly above the industry average of 8.16%.
The last Return On Invested Capital (2.00%) for CCRN is well below the 3 year average (21.83%), which needs to be investigated, but indicates that CCRN had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.3% | ||
| ROE | -0.42% | ||
| ROIC | 2% |
ROA(3y)16.2%
ROA(5y)5.97%
ROE(3y)33.65%
ROE(5y)11.41%
ROIC(3y)21.83%
ROIC(5y)14.11%
1.3 Margins
CCRN has a Operating Margin of 0.91%. This is in the lower half of the industry: CCRN underperforms 60.00% of its industry peers.
CCRN's Operating Margin has improved in the last couple of years.
With a Gross Margin value of 20.91%, CCRN is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of CCRN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.91% | ||
| PM (TTM) | N/A | ||
| GM | 20.91% |
OM growth 3Y54.33%
OM growth 5Y25.36%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y-2.78%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CCRN is creating value.
CCRN has less shares outstanding than it did 1 year ago.
CCRN has less shares outstanding than it did 5 years ago.
There is no outstanding debt for CCRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CCRN has an Altman-Z score of 5.54. This indicates that CCRN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CCRN (5.54) is better than 87.62% of its industry peers.
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.54 |
ROIC/WACC0.22
WACC9.09%
2.3 Liquidity
A Current Ratio of 2.79 indicates that CCRN has no problem at all paying its short term obligations.
The Current ratio of CCRN (2.79) is better than 86.67% of its industry peers.
A Quick Ratio of 2.79 indicates that CCRN has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 2.79, CCRN belongs to the best of the industry, outperforming 87.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.79 |
3. Growth
3.1 Past
The earnings per share for CCRN have decreased strongly by -76.74% in the last year.
The Earnings Per Share has been growing by 76.23% on average over the past years. This is a very strong growth
The Revenue for CCRN has decreased by -35.18% in the past year. This is quite bad
CCRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.86% yearly.
EPS 1Y (TTM)-76.74%
EPS 3Y68.74%
EPS 5Y76.23%
EPS Q2Q%-69.23%
Revenue 1Y (TTM)-35.18%
Revenue growth 3Y34.16%
Revenue growth 5Y19.86%
Sales Q2Q%-28.75%
3.2 Future
Based on estimates for the next years, CCRN will show a very negative growth in Earnings Per Share. The EPS will decrease by -32.13% on average per year.
Based on estimates for the next years, CCRN will show a very negative growth in Revenue. The Revenue will decrease by -13.67% on average per year.
EPS Next Y-75.41%
EPS Next 2Y-48.64%
EPS Next 3Y-32.13%
EPS Next 5YN/A
Revenue Next Year-33.32%
Revenue Next 2Y-21.04%
Revenue Next 3Y-13.67%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 26.06, which means the current valuation is very expensive for CCRN.
CCRN's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of CCRN to the average of the S&P500 Index (27.34), we can say CCRN is valued inline with the index average.
CCRN is valuated quite expensively with a Price/Forward Earnings ratio of 31.29.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CCRN is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of CCRN to the average of the S&P500 Index (23.61), we can say CCRN is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.06 | ||
| Fwd PE | 31.29 |
4.2 Price Multiples
CCRN's Enterprise Value to EBITDA ratio is in line with the industry average.
96.19% of the companies in the same industry are more expensive than CCRN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.07 | ||
| EV/EBITDA | 17.01 |
4.3 Compensation for Growth
A cheap valuation may be justified as CCRN's earnings are expected to decrease with -32.13% in the coming years.
PEG (NY)N/A
PEG (5Y)0.34
EPS Next 2Y-48.64%
EPS Next 3Y-32.13%
5. Dividend
5.1 Amount
CCRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CROSS COUNTRY HEALTHCARE INC
NASDAQ:CCRN (1/8/2025, 8:00:01 PM)
After market: 18.24 0 (0%)18.24
+0.02 (+0.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners106.98%
Inst Owner Change-0.01%
Ins Owners5.59%
Ins Owner Change-0.41%
Market Cap600.46M
Analysts52.31
Price Target17.81 (-2.36%)
Short Float %10.41%
Short Ratio3.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.89%
Min EPS beat(2)-26.01%
Max EPS beat(2)22.23%
EPS beat(4)3
Avg EPS beat(4)2.25%
Min EPS beat(4)-26.01%
Max EPS beat(4)22.23%
EPS beat(8)6
Avg EPS beat(8)5.46%
EPS beat(12)10
Avg EPS beat(12)7.75%
EPS beat(16)14
Avg EPS beat(16)22.92%
Revenue beat(2)0
Avg Revenue beat(2)-0.45%
Min Revenue beat(2)-0.49%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-0.29%
Min Revenue beat(4)-0.63%
Max Revenue beat(4)0.37%
Revenue beat(8)3
Avg Revenue beat(8)0.3%
Revenue beat(12)6
Avg Revenue beat(12)0.74%
Revenue beat(16)10
Avg Revenue beat(16)3.26%
PT rev (1m)11.91%
PT rev (3m)-6.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-63.78%
EPS NY rev (1m)0.22%
EPS NY rev (3m)2.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-19.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.06 | ||
| Fwd PE | 31.29 | ||
| P/S | 0.41 | ||
| P/FCF | 6.07 | ||
| P/OCF | 5.56 | ||
| P/B | 1.41 | ||
| P/tB | 2.47 | ||
| EV/EBITDA | 17.01 |
EPS(TTM)0.7
EY3.84%
EPS(NY)0.58
Fwd EY3.2%
FCF(TTM)3
FCFY16.47%
OCF(TTM)3.28
OCFY17.98%
SpS43.99
BVpS12.9
TBVpS7.38
PEG (NY)N/A
PEG (5Y)0.34
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.3% | ||
| ROE | -0.42% | ||
| ROCE | 2.77% | ||
| ROIC | 2% | ||
| ROICexc | 2.31% | ||
| ROICexgc | 4.13% | ||
| OM | 0.91% | ||
| PM (TTM) | N/A | ||
| GM | 20.91% | ||
| FCFM | 6.83% |
ROA(3y)16.2%
ROA(5y)5.97%
ROE(3y)33.65%
ROE(5y)11.41%
ROIC(3y)21.83%
ROIC(5y)14.11%
ROICexc(3y)22.07%
ROICexc(5y)14.26%
ROICexgc(3y)32.8%
ROICexgc(5y)21.74%
ROCE(3y)30.3%
ROCE(5y)19.59%
ROICexcg growth 3Y52.91%
ROICexcg growth 5Y28.64%
ROICexc growth 3Y65.44%
ROICexc growth 5Y37.16%
OM growth 3Y54.33%
OM growth 5Y25.36%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y-2.78%
F-Score5
Asset Turnover2.42
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 49.48% | ||
| Cap/Sales | 0.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 342.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.79 | ||
| Altman-Z | 5.54 |
F-Score5
WACC9.09%
ROIC/WACC0.22
Cap/Depr(3y)72.91%
Cap/Depr(5y)55.1%
Cap/Sales(3y)0.48%
Cap/Sales(5y)0.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.74%
EPS 3Y68.74%
EPS 5Y76.23%
EPS Q2Q%-69.23%
EPS Next Y-75.41%
EPS Next 2Y-48.64%
EPS Next 3Y-32.13%
EPS Next 5YN/A
Revenue 1Y (TTM)-35.18%
Revenue growth 3Y34.16%
Revenue growth 5Y19.86%
Sales Q2Q%-28.75%
Revenue Next Year-33.32%
Revenue Next 2Y-21.04%
Revenue Next 3Y-13.67%
Revenue Next 5YN/A
EBIT growth 1Y-91.44%
EBIT growth 3Y107.05%
EBIT growth 5Y50.25%
EBIT Next Year-55.63%
EBIT Next 3Y-21.19%
EBIT Next 5YN/A
FCF growth 1Y109.14%
FCF growth 3Y118.12%
FCF growth 5Y70.24%
OCF growth 1Y91.45%
OCF growth 3Y109.05%
OCF growth 5Y63.92%